
    
      Patients with newly diagnosed untreated acute graft versus host disease grades 2-4 will
      receive methylprednisolone 2.5mg/kg intravenously and randomised to receive or not receive
      allogeneic human mesenchymal stromal cells 2X10E6 intravenously on two occasions at weekly
      intervals
    
  